Why Ultragenyx Pharmaceutical Stock Has Dropped 40% In The Last Quarter
- Tuesday, November 19, 2019, 7:21
- Market
- Add a comment
Ultragenyx Pharmaceuticals (NASDAQ: RARE), a biopharmaceutical company focused on serious rare and ultra-rare genetic diseases, has seen its stock price decline by close to 40% over the last 3 months. The decline could be due to the fact that the company posted wider than expected losses…
About the Author
admin123 has written 23544 stories on this site.
